Declining systolic blood pressure may serve as an important clinical indicator of concurrent cognitive decline in older women.

Women with long COVID experience higher neurologic symptom burden and worse fatigue than men, regardless of hospitalization status.

The FDA has approved mFlusiva, the first mRNA-based influenza vaccine, for adults aged 50 years and older, with accelerated approval for those 65 and older.

A history of traumatic brain injury may reduce the diagnostic accuracy of blood biomarkers used to detect Alzheimer disease ...

The FDA has approved Orzeyful (oveporexton), a first-in-class oral orexin receptor 2 agonist, for the treatment of adult narcolepsy type 1.

Poor self-reported sleep quality is associated with larger choroid plexus volume and neurodegeneration in cognitively unimpaired older adults.

Obstructive sleep apnea is linked to poorer memory performance and a higher estimated risk for dementia in cognitively unimpaired middle-aged adults.

Pediatric patients with chronic migraine may see reductions in headache frequency and disability with onabotulinumtoxin A.

As autism therapy utilization and spending expand rapidly, federal agencies are pushing for state oversight to manage Medicaid budget policy.

An accelerated pace of biological aging may predict decreased brain volume, cognitive decline, and incident dementia among older adults.

Any occupational exposure to pesticides is associated with an increased risk for amyotrophic lateral sclerosis.

Premature menopause, usually occurring among women 40 years and younger, is associated with a higher risk for developing hypertension, ...